Biopharmx (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.12, Fidelity Earnings reports.
Biopharmx stock traded down $0.01 during trading on Tuesday, reaching $0.39. The stock had a trading volume of 12,946 shares, compared to its average volume of 610,260. Biopharmx has a 52-week low of $0.30 and a 52-week high of $6.75.
In related news, major shareholder Vivo Capital Viii, Llc sold 327,870 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $1.02, for a total transaction of $334,427.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Separately, Maxim Group set a $3.00 target price on Biopharmx and gave the stock a “buy” rating in a research note on Tuesday, June 25th.
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.